BRCAness as a biomarker of susceptibility to PARP inhibitors in glioblastoma multiforme

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.creatorXavier, Mary-Ann Elvina-
Autor(es): dc.creatorRezende, Fernando-
Autor(es): dc.creatorAlmeida, Ricardo Titze de-
Autor(es): dc.creatorCornelissen, Bart-
Data de aceite: dc.date.accessioned2022-08-15T13:42:12Z-
Data de disponibilização: dc.date.available2022-08-15T13:42:12Z-
Data de envio: dc.date.issued2022-04-12-
Data de envio: dc.date.issued2022-04-12-
Data de envio: dc.date.issued2020-
Fonte completa do material: dc.identifierhttps://repositorio.unb.br/handle/10482/43377-
Fonte completa do material: dc.identifierhttps://doi.org/10.3390/biom11081188-
Fonte completa do material: dc.identifierhttps://orcid.org/0000-0001-8125-8879-
Fonte completa do material: dc.identifierhttps://orcid.org/0000-0002-5019-4742-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/capes/714324-
Descrição: dc.descriptionGlioblastoma multiforme (GBM) is the most common primary brain cancer. GBMs commonly acquire resistance to standard-of-care therapies. Among the novel means to sensitize GBM to DNA-damaging therapies, a promising strategy is to combine them with inhibitors of the DNA damage repair (DDR) machinery, such as inhibitors for poly(ADP-ribose) polymerase (PARP). PARP inhibitors (PARPis) have already shown efficacy and have received regulatory approval for breast, ovarian, prostate, and pancreatic cancer treatment. In these cancer types, after PARPi administration, patients carrying specific mutations in the breast cancer 1 (BRCA1) and 2 (BRCA2) suppressor genes have shown better response when compared to wild-type carriers. Mutated BRCA genes are infrequent in GBM tumors, but their cells can carry other genetic alterations that lead to the same phenotype collectively referred to as ‘BRCAness’. The most promising biomarkers of BRCAness in GBM are related to isocitrate dehydrogenases 1 and 2 (IDH1/2), epidermal growth factor receptor (EGFR), phosphatase and tensin homolog (PTEN), MYC proto-oncogene, and estrogen receptors beta (ERβ). BRCAness status identified by accurate biomarkers can ultimately predict responsiveness to PARPi therapy, thereby allowing patient selection for personalized treatment. This review discusses potential biomarkers of BRCAness for a ‘precision medicine’ of GBM patients.-
Formato: dc.formatapplication/pdf-
Publicador: dc.publisherMDPI-
Direitos: dc.rightsAcesso Aberto-
Direitos: dc.rights(CC BY)-
Palavras-chave: dc.subjectGlioblastoma multiforme-
Palavras-chave: dc.subjectProteínas-
Título: dc.titleBRCAness as a biomarker of susceptibility to PARP inhibitors in glioblastoma multiforme-
Tipo de arquivo: dc.typelivro digital-
Aparece nas coleções:Repositório Institucional – UNB

Não existem arquivos associados a este item.